Date |
Time |
Agenda |
18-Jun |
10 - 11 AM |
Course Introduction, Stephen Oliver |
| |
11 - 12 Noon |
Regulatory Issues in Drug Development, Ned Braunstein |
| 19-Jun |
10 - 11 AM |
Economic Impact of New Drug Development, Jan Blustein |
|
11 - 12 Noon |
Financial Conflicts of Interest, Bruce Cronstein |
20-Jun |
10 - 11 AM |
Critical Analysis of Clinical Trial Design, Mark Schwartz |
|
11 - 12 Noon |
Generic Drugs, Robert Holzman |
| 21-Jun |
10 - 11 AM |
Developing Inexpensive Drugs for the Third World, Sheldon Segal |
|
11 - 12 Noon |
Intellectural Property, Abram Goldfinger |
| 22-Jun |
10 - 11 AM |
Ethics in Drug Development, Elan Czeisler |
| |
11 - 12 Noon |
Post Marketing Surveillance, Manfred Hauben |
25-Jun |
10 - 11 AM |
Orphan Drug Development, Stephen Oliver |
| |
11 - 12 Noon |
Pharmacogenomics and Pharmacogenetics, Harry Ostrer |
26-Jun |
10 - 11 AM |
Drug Discovery: From Bench to Bedside, Fred Valentine |
| |
11 - 12 Noon |
Student Presentations |
27-Jun |
10 - 11 AM |
The Peer Review Process and Drug Studies, Lawrence Altman |
| |
11 - 12 Noon |
Student Presentations |
28-Jun |
10 - 11 AM |
Student Presentations |
| |
11 - 12 Noon |
Student Presentations |
29-Jun |
10 - 11 AM |
Student Presentations |
| |
11 - 12 Noon |
Student Presentations |
